Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression

July 30, 2013 updated by: Sanja Sadevirta, University of Helsinki
o determine effects of hula-hooping on android obesity, metabolic parameters and adipose tissue (AT) gene expression.

Study Overview

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, FI-00290
        • Department of Medicine, University of Helsinki

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 18 and 70 years
  • central adiposity as measured by the waist circumference (>80 cm in females and >94 cm in males) (9)
  • ability to hula-hoop for a minimum of 2 minutes and to have the necessary space available for this activity either at home or at work
  • ability to communicate meaningfully with the investigator and legal competence to provide written informed consent

Exclusion Criteria:

  • clinical or biochemical evidence of disease other than obesity as judged by history, physical examination and standard laboratory tests
  • excessive use of alcohol, i.e., over 20 g/day
  • use of medications known to affect glucose or lipid metabolism and
  • pregnancy or lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Walking
WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
Active Comparator: Hula-hooping
HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Android obesity
Time Frame: 6weeks
The primary objective was to evaluate the change in the % fat in the android region as measured by DEXA during 6 weeks of HULA as compared to WALK
6weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
metabolic parameters
Time Frame: 6weeks
The secondary objectives included the comparison of differences in waist circumference (cm), relative and absolute trunk and limb muscle mass as measured by DEXA (% and kg), fasting plasma glucose (mmol/l), fasting serum insulin (mU/l), liver enzymes (U/l), fasting plasma LDL and HDL cholesterol and triglycerides (mmol/l). Gene expression was analyzed in adipose tissue biopsies collected before and after each exercise intervention.
6weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
adipose tissue inflammation
Time Frame: 6weeks

To determine the effects of HULA compared to WALK on adipose tissue inflammation, a needle aspiration biopsy of abdominal s.c. adipose tissue was taken under local anesthesia with lidocaine before and after each exercise intervention. The adipose tissue sample was immediately frozen in liquid nitrogen and then stored at -80°C until analysis. Total RNA from s.c. AT was isolated.Relative quantification for the genes of interest (see list below) was carried out using normalization to the 36B4 and β-actin mRNA values.

ABCA1 Adiponectin ANGPTL8 CHOP CD4 CD8 CD68 ETFDH FOXP3 GLUT4 MCP-1 MRC-1 PGC-1α VEGF-A β-actin

6weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (Actual)

March 1, 2012

Study Completion (Actual)

March 1, 2012

Study Registration Dates

First Submitted

June 18, 2013

First Submitted That Met QC Criteria

July 30, 2013

First Posted (Estimate)

July 31, 2013

Study Record Updates

Last Update Posted (Estimate)

July 31, 2013

Last Update Submitted That Met QC Criteria

July 30, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • HULA 233401
  • HULA233401 (Other Identifier: HUS Tietu)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Android Obesity, Metabolic Parameters and Adipose Tissue (AT) Gene Expression

Clinical Trials on Exercise

3
Subscribe